In Vivo Kinetics of Indoxyl Sulfate in Humans and Its Renal Interaction with Angiotensin-Converting Enzyme Inhibitor Quinapril in Rats

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2012-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.111.187732PMID 22389425
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprar Clinical Pharmacokinetics: Concepts and Applications, 4/e | Rowland and Tozer | 9780781750097 | Lippincott Williams & Wilkins

  2010cited by this paper
• Renal Organic Anion Transporter-Mediated Drug-Drug Interaction between Gemcabene and Quinapril

  2009cited by this paper
• Characterization of uremic toxin transport by organic anion transporters in the kidney.

  2004cited by this paper
• Interactions of human organic anion as well as cation transporters with indoxyl sulfate.

  2003influential reference
• Review on uremic toxins: classification, concentration, and interindividual variability.

  2003cited by this paper
• The Effect of Chronic Renal Failure on Hepatic Drug Metabolism and Drug Disposition

  2003influential reference
• Pharmacokinetics and tissue distribution of uraemic indoxyl sulphate in rats

  2003influential reference
• Ambulatory 24-h colonic manometry in healthy humans.

  2001cited by this paper
• Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism.

  1996cited by this paper
• Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis.

  1994influential reference
• Clinical pharmacokinetics: Concepts and applications (2nd edn.)

  1989cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Displacement by Anionic Drugs of Endogenous Ligands Bound to Albumin in Uremic Serum

  1988cited by this paper
• Determination of indican and tryptophan in normal and uraemic patients by high-performance liquid chromatography with a new electrochemical detector.

  1986cited by this paper
• The effects of tryptophan and tyrosine on human mood and performance.

  1984cited by this paper
• Decreased drug binding in uraemia: effect of indoxyl sulphate and other endogenous substances on the binding of drugs and dyes to human albumin.

  1982cited by this paper
• Short-term and repetitive administration of oral tryptophan in normal men. Effects on blood tryptophan, serotonin, and kynurenine concentrations.

  1981cited by this paper
• The acute effects of oral (--)-tryptophan in human subjects.

  1975cited by this paper
• Quantitative studies on the urinary excretion of indoxyl sulfate (indican) in man following administration of L-tryptophan and acetyl-L-tryptophan.

  1966cited by this paper

• Transporter-Mediated Interactions Between Uremic Toxins and Drugs: A Hidden Driver of Toxicity in Chronic Kidney Disease

  2025influential citation
• Western diet exacerbates a murine model of Balkan nephropathy.

  2024cites this paper
• Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2

  2021cites this paper
• Effects of antibiotics on the pharmacokinetics of indoxyl sulfate, a nephro-cardiovascular toxin

  2020cites this paper
• Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination.

  2020cites this paper
• Analysis of membrane transport mechanisms of endogenous substrates using chromatographic techniques.

  2019cites this paper
• Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease

  2018cites this paper
• Renal organic anion transporters in drug–drug interactions and diseases

  2018cites this paper
• Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.

  2017cites this paper
• Emerging targets and new small molecule therapies in Parkinson's disease treatment.

  2016cites this paper
• The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.

  2015cites this paper
• Does the Adequacy Parameter Kt/Vurea Reflect Uremic Toxin Concentrations in Hemodialysis Patients?

  2013cites this paper
• Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.

  2013cites this paper